Cannabis News
Ashamed of Your Body and Feel Uncomfortable in Your Own Skin ?
Published
1 month agoon
By
admin
Pioneering research from Columbia University in New York suggests that psilocybin, the key component in magic mushrooms, may help people with body dysmorphic disorder (BDD). The study, published in Psychedelics, looked at how psilocybin affected brain activity in BDD patients, and it found significant alterations in brain connections that might help lessen the disorder’s obsessive thinking patterns.
Understanding Body Dysmorphic Disorder: A Hidden Struggle Beneath the Surface
A severe mental illness known as body dysmorphic disorder (BDD) is typified by an obsessive, illogical fixation on perceived physical defects that are usually undetectable to others. Extreme emotional anguish brought on by these compulsive worries might result in social isolation, anxiety, and depression. BDD sufferers frequently get fixated on characteristics like body type, facial features, or skin texture. They continuously try to “correct” these flaws, usually by over-grooming, cosmetic surgery, or social distancing.
For many patients, especially those with severe instances, traditional therapies including cognitive-behavioral therapy (CBT) and antidepressant drugs have had only patchy success. This has left a major percentage of the BDD population in search of more effective treatments. In this recent study, a single 25 mg dosage of psilocybin, the hallucinogenic ingredient in magic mushrooms, was given to eight persons with moderate-to-severe BDD using COMP360, a synthetic formulation made by COMPASS Pathways. Brain imaging and symptom evaluations were performed on individuals following treatment to better understand how psilocybin can help those who are caught in obsessive thinking cycles.
Study Uncovers Long-Lasting Symptom Relief Through Psilocybin Treatment
The study found that a single dose of psilocybin improved brain connectivity significantly, especially in networks involved in cognitive control and emotional regulation. One of the most significant findings was increased activity in the Executive Control Network (ECN), a brain area that controls decision-making, cognitive flexibility, and goal-directed behavior. This increased connection in the ECN implies that psilocybin may aid patients in breaking away from the inflexible and compulsive cognitive processes that define body dysmorphic disorder (BDD).
Additionally, the ECN showed strengthened connections with the Default Mode Network (DMN), a brain region involved in self-reflection and internal thought processes, often hyperactive in individuals with BDD. The improved communication between these networks may reduce the intensity of negative self-focused rumination, allowing patients to see themselves and their perceived flaws in a less critical and more objective light. Another key player, the Salience Network, which helps the brain prioritize important stimuli and emotions, also demonstrated improved connectivity. This shift could potentially allow individuals with BDD to redirect attention away from their obsessive concerns toward more balanced and healthy thought processes.
Crucially, these alterations in brain connection were long-lasting. Following a single psilocybin session, research participants reported continuing remission from their BDD symptoms, with benefits lasting for as long as 12 weeks. This prolonged duration of symptom alleviation is especially significant since it implies that psilocybin’s effects on brain activity may provide long-term advantages, in contrast to traditional therapies that frequently need ongoing usage in order to preserve improvements.
These results demonstrate the ability of psilocybin to support long-term, more permanent changes in brain activity that promote emotional resilience and a healthy sense of self in addition to its ability to reduce symptoms in the short term.
A Promising Step Forward, But More Research Is Essential
While psilocybin therapy for body dysmorphic disorder (BDD) has advanced significantly with this trial, the researchers warn that more thorough research is required before it can be widely used. Although there is cause for optimism, the results also point to significant shortcomings that need to be resolved in more research in order to properly comprehend the safety and efficacy of psilocybin for this particular issue.
The small sample size of this study—just eight participants—is one of its main shortcomings. Though these were encouraging results, larger and more varied studies are needed to demonstrate that psilocybin may reliably provide comparable benefits in a broader population of BDD sufferers. It is also challenging to ascertain whether the claimed benefits were caused by the effects of psilocybin or were affected by other variables, such as the placebo effect or the controlled atmosphere in which the individuals were treated because the study did not include a placebo control group.
Dr. Xi Zhu, the lead researcher, and his team underline the need for randomized controlled trials (RCTs) in appropriately assessing psilocybin’s treatment potential for BDD. These studies would compare the effects of psilocybin to those of placebo or other therapies in a double-blind environment, with neither the subjects nor the researchers knowing which therapy was given. Such thorough research would give greater proof for psilocybin’s efficacy and aid in the development of standardized dose regimens, both of which are presently missing in the area of psychedelic-assisted therapy.
Furthermore, the precise processes behind the long-lasting alterations in brain connections that psilocybin appears to bring about and which are correlated with the alleviation of symptoms remain unclear. It will take further investigation to learn how psilocybin interacts with the brain at the molecular level and why its effects tend to last long after the substance has left the body. Comprehending these pathways may aid in the improvement of psilocybin-based treatments and may augment their efficacy.
The results of the study represent a significant advancement in the search for new treatments for disorders like BDD, which have traditionally resisted standard medical interventions, notwithstanding these obstacles. With the ongoing advancements in psychedelic research, psilocybin may prove to be an effective treatment for a variety of mental health conditions marked by compulsive thinking and skewed self-image, including BDD.
In summary, much more research is needed to confirm psilocybin’s promise as a therapy for BDD, even if the current study offers a promising basis. Progress in this study and the realization of psychedelics’ full therapeutic potential will require larger trials, placebo controls, and a better comprehension of the drug’s effects on the brain.
Bottom Line
This groundbreaking study demonstrates psilocybin’s potential as a unique therapy for Body Dysmorphic Disorder (BDD), which can provide long-term symptom alleviation by modifying brain connections. The increased connection across brain networks involved in cognitive control, emotional regulation, and self-reflection shows that psilocybin may help lessen obsessive and negative thinking patterns. While the findings are encouraging, particularly for individuals who are resistant to standard therapy, further research with bigger sample sizes and controlled trials is required to validate the efficacy and safety of psilocybin for BDD.
CANNABIS LOWERS BMI AND BODY INFLAMMATION? READ ON…
HOW DOES CANNABIS HELP LOWER BMI AND BODY INFLAMMATION?
You may like
-
Driving Under The Influence of THC In Vermont
-
Long shot adult-use legalization effort launches in anti-marijuana Idaho
-
Latest Trump Weed Rumor – Trump Will Federally Deschedule and Decriminalize Cannabis, but Not Legalize It
-
Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em
-
I Had Just One Puff
-
Marijuana firms Eaze, Green Dragon find new life after $10 million capital infusion
Cannabis News
Latest Trump Weed Rumor – Trump Will Federally Deschedule and Decriminalize Cannabis, but Not Legalize It
Published
23 hours agoon
November 14, 2024By
admin
In a recent interview, former New Jersey Governor Chris Christie made headlines by asserting that President-elect Donald Trump will pursue significant reforms in federal policies regarding marijuana and cryptocurrency. As the nation grapples with evolving attitudes toward cannabis and the burgeoning digital currency market, Christie’s predictions have ignited discussions about the potential implications of such changes on both industries. This article delves into Christie’s insights, the current state of marijuana and cryptocurrency regulations, and the broader implications of these anticipated reforms.
The Current Landscape of Marijuana Legislation
Federal vs. State Laws
Marijuana remains classified as a Schedule I substance under the Controlled Substances Act (CSA), which places it in the same category as heroin and LSD. This classification has created a complex legal landscape where states have moved to legalize cannabis for medical and recreational use, while federal law continues to impose strict prohibitions. As of now, over 30 states have legalized marijuana in some form, leading to a burgeoning industry that generates billions in revenue.
Challenges Faced by the Cannabis Industry
Despite its legality in many states, the cannabis industry faces significant hurdles due to federal restrictions. These challenges include:
-
Banking Access: Many banks are hesitant to work with cannabis businesses due to fear of federal repercussions, forcing these businesses to operate largely in cash.
-
Taxation Issues: The IRS enforces Section 280E of the tax code, which prohibits businesses engaged in illegal activities from deducting normal business expenses, leading to disproportionately high tax burdens for cannabis companies.
-
Interstate Commerce: The lack of federal legalization prevents cannabis businesses from operating across state lines, limiting their growth potential.
Chris Christie’s Perspective on Marijuana Reform
Christie, a former presidential candidate known for his tough stance on drugs during his tenure as governor, has evolved his views on marijuana over the years. In his recent statements, he emphasized that Trump is likely to pursue descheduling cannabis, which would remove it from the Schedule I classification. This move would not only provide clarity for businesses operating in legal markets but also open avenues for banking and investment.
Christie highlighted that descheduling would allow for a more regulated market where safety standards could be established, thus protecting consumers. He believes that this approach aligns with a growing consensus among Americans who support legalization and recognize the potential benefits of cannabis use for both medical and recreational purposes.
The Future of Cryptocurrency Regulation = The Rise of Cryptocurrencies
Cryptocurrencies have surged in popularity over the past decade, with Bitcoin leading the charge as the first decentralized digital currency. The market has expanded to include thousands of alternative coins (altcoins), each with unique features and use cases. As cryptocurrencies gain traction among investors and consumers alike, regulatory scrutiny has intensified.
Current Regulatory Challenges
The cryptocurrency market faces several regulatory challenges that hinder its growth and adoption:
-
Lack of Clarity: Regulatory frameworks vary significantly across states and countries, creating confusion for investors and businesses.
-
Fraud and Scams: The rapid growth of cryptocurrencies has led to an increase in fraudulent schemes targeting unsuspecting investors.
-
Consumer Protection: Without clear regulations, consumers are often left vulnerable to risks associated with volatile markets.
Christie’s Vision for Crypto Regulation
Christie believes that under Trump’s leadership, there will be an effort to find a “sweet spot” for cryptocurrency regulation balancing innovation with consumer protection. He argues that overly stringent regulations could stifle growth in this emerging sector while too little oversight could expose consumers to significant risks.
In his view, a balanced regulatory framework would include:
1. Clear Definitions: Establishing clear definitions for different types of cryptocurrencies and tokens to differentiate between securities and utility tokens.
2. Consumer Protections: Implementing measures to protect investors from fraud while promoting transparency within the market.
3. Encouraging Innovation: Creating an environment conducive to innovation by allowing startups to thrive without excessive regulatory burdens.
Christie’s insights reflect a growing recognition among policymakers that cryptocurrencies are here to stay and that appropriate regulations are necessary to foster growth while safeguarding consumers.
Implications of Proposed Reforms
Economic Impact
The potential reforms proposed by Christie could have far-reaching economic implications:
-
Job Creation: Legalizing marijuana at the federal level could lead to significant job creation within the cannabis industry—from cultivation and production to retail sales.
-
Investment Opportunities: Descheduling cannabis would open up investment opportunities for institutional investors who have been hesitant due to federal restrictions.
-
Boosting Local Economies: Legal cannabis markets have proven beneficial for local economies through increased tax revenues and job creation.
Similarly, clear regulations around cryptocurrencies could stimulate investment in blockchain technology and related industries, fostering innovation and economic growth.
Social Justice Considerations
Both marijuana legalization and sensible cryptocurrency regulations have social justice implications:
-
Addressing Past Injustices: Legalizing marijuana could help rectify past injustices related to drug enforcement policies that disproportionately affected marginalized communities.
-
Financial Inclusion: Cryptocurrencies offer opportunities for financial inclusion for those underserved by traditional banking systems, particularly in low-income communities.
Political Landscape
The political landscape surrounding these issues is complex. While there is bipartisan support for marijuana reform among certain lawmakers, challenges remain in overcoming entrenched opposition. Similarly, cryptocurrency regulation has garnered attention from both sides of the aisle but requires collaboration to establish effective frameworks.
Conclusion
Chris Christie’s predictions about President-elect Donald Trump’s approach to federal marijuana descheduling and cryptocurrency regulation suggest a potential shift in U.S. policy that could significantly reshape both industries. As public opinion evolves on these issues, lawmakers have an opportunity to enact meaningful reforms that promote economic growth while ensuring consumer protection. The anticipated changes could foster a more robust cannabis industry that contributes positively to the economy and addresses social justice concerns, while clear regulatory frameworks for cryptocurrencies could encourage innovation and protect consumers in the digital economy. Stakeholders in both sectors are closely watching these developments, eager to see how potential reforms might impact their futures. While the realization of Christie’s predictions remains uncertain, it’s clear that the conversation around marijuana and cryptocurrency regulation is ongoing and far from settled.
TRUMP 2.0 ON CANNABIS REFORM, READ ON…
TRUMP 2.0 ON FEDERAL CANNABIS REFORM – WHAT DO WE KNOW?
Cannabis News
Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em
Published
2 days agoon
November 13, 2024By
admin
On Thursday, November 7th, Vince Sliwoski, Aaron Pelley and Fred Rocafort held a post election discussion “Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em”. Watch the replay!
Key Takeaways from the “Smoke ’em if You’ve Got ’em – 2024 Post Election Cannabis Wrap” Webinar:
- Panelists:
- Vince Sliwoski: Oregon Business lawyer specializing in cannabis and commercial real estate.
- Aaron Pelley: Experienced in cannabis law since Washington’s legalization in 2012.
- Fred Rocafort: Trademark attorney working closely with the cannabis team.
- Election Results Overview:
- Most 2024 cannabis ballot measures did not pass.
- Florida, South Dakota, and North Dakota saw failures.
- Nebraska became the 39th state to legalize cannabis for medical use when it passed two cannabis initiatives, Initiatives 437 and 438.
- Federal and State-Level Developments:
- Medical use is currently legal in 38 states, and 24 states allow recreational use.
- Republican support for marijuana legalization is growing.
- Federal Policy Implications:
- Schedule III Rescheduling: The process to move cannabis to Schedule III is ongoing, which could significantly impact the industry.
- Importance of Federal Appointments: The future of cannabis policy depends heavily on who is appointed to key positions in the administration.
- International and Domestic Trade:
- Schedule III status could ease import/export restrictions on cannabis.
- Unified control of House, Senate, and presidency might expedite legislative progress.
- Economic and Industry Impact:
- Cannabis stocks experienced volatility post-election, reflecting investor uncertainty.
- Federal legalization and banking reforms are crucial for industry stability and growth.
- Future Outlook:
- The potential for federal rescheduling remains strong, with hearings scheduled for early 2025.
- State-level initiatives and regulatory developments will continue to shape the industry.
“How Long Does One Puff of Weed Stay in Your System?”… This topic can be difficult to answer since it is dependent on elements such as the size of the hit and what constitutes a “one hit.” If you take a large bong pull then cough, it might linger in your system for 5-7 days. A moderate dose from a joint can last 3-5 days, whereas a few hits from a vaporizer may last 1-3 days.
The length of time that marijuana stays in the body varies based on a number of factors, including metabolism, THC levels, frequency of use, and hydration.
Delta-9-tetrahydrocannabinol, or THC, is the primary psychoactive component of cannabis. THC and its metabolites, which remain in your body long after the effects have subsided, are detected by drug tests.
Since these metabolites are fat-soluble, they cling to bodily fat molecules. They could thus take a while to fully pass through your system, particularly if your body fat percentage is higher.
THC is absorbed by tissues and organs (including the brain, heart, and fat) and converted by the liver into chemicals such as 11-hydroxy-THC and carboxy-THC. Cannabis is eliminated in feces at a rate of around 65%, while urine accounts for 20%. The leftover amount might be kept within the body.
THC deposited in bodily tissues ultimately re-enters the circulation and is processed by the liver. For frequent users, THC accumulates in fatty tissues quicker than it can be removed, thus it may be detectable in drug tests for days or weeks following consumption.
The detection time varies according to the amount and frequency of cannabis usage. Higher dosages and regular usage result in longer detection times.
The type of drug test also affects detection windows. Blood and saliva tests typically detect cannabis metabolites for shorter periods, while urine and hair samples can reveal use for weeks or even months. In some cases, hair tests have detected cannabis use over 90 days after consumption.
Detection Windows for Various Cannabis Drug Tests
Urine Tests
Among all drug tests, urine testing is the most commonly used method for screening for drug use in an individual.
Detection times vary, but a 2017 review suggests the following windows for cannabis in urine after last use:
– Single-use (e.g., one joint): up to 3 days
– Moderate use (around 4 times a week): 5–7 days
– Chronic use (daily): 10–15 days
– Chronic heavy use (multiple times daily): over 30 days
Blood Tests
Blood tests generally detect recent cannabis use, typically within 2–12 hours after consumption. However, in cases of heavy use, cannabis has been detected up to 30 days later. Chronic heavy use can extend the detection period in the bloodstream.
Saliva Tests
THC can enter saliva through secondhand cannabis smoke, but THC metabolites are only present if you’ve personally smoked or ingested cannabis.
Saliva testing has a short detection window and can sometimes identify cannabis use on the same day. A 2020 review found that THC was detectable in the saliva of frequent users for up to 72 hours after use, and it may remain in saliva longer than in blood following recent use.
In areas where cannabis is illegal, saliva testing is often used for roadside screenings.
Hair Tests
Hair follicle tests can detect cannabis use for up to 90 days. After use, cannabinoids reach the hair follicles through small blood vessels and from sebum and sweat surrounding the hair.
Hair grows at approximately 0.5 inches per month, so a 1.5-inch segment of hair close to the scalp can reveal cannabis use over the past three months.
Factors Affecting THC and Metabolite Retention
The length of time THC and its metabolites stay in your system depends on various factors. Some, like body mass index (BMI) and metabolic rate, relate to individual body processing, not the drug itself.
Other factors are specific to cannabis use, including:
– Dosage: How much you consume
– Frequency: How often you use cannabis
– Method of consumption: Smoking, dabbing, edibles, or sublingual
– THC potency: Higher potency can extend detection time
Higher doses and more frequent use generally extend THC retention. Cannabis consumed orally may remain in the system slightly longer than smoked cannabis, and stronger cannabis strains, higher in THC, may also stay detectable for a longer period.
How Quickly Do the Effects of Cannabis Set In?
When smoking cannabis, effects appear almost immediately, while ingested cannabis may take 1–3 hours to peak.
The psychoactive component THC produces a “high” with common effects such as:
– Altered senses, including perception of time
– Mood changes
– Difficulty with thinking and problem-solving
– Impaired memory
Other short-term effects can include:
– Anxiety and confusion
– Decreased coordination
– Dry mouth and eyes
– Nausea or lightheadedness
– Trouble focusing
– Increased appetite
– Rapid heart rate
– Restlessness and sleepiness
In rare cases, high doses may lead to hallucinations, delusions, or acute psychosis.
Regular cannabis use may have additional mental and physical effects. While research is ongoing, cannabis use may increase the risk of:
– Cognitive issues like memory loss
– Cardiovascular problems including heart disease and stroke
– Respiratory illnesses such as bronchitis or lung infections
– Mood disorders like depression and anxiety
Cannabis use during pregnancy can negatively impact fetal growth and development.
Duration of Effects
Short-term effects generally taper off within 1–3 hours, but for chronic users, some long-term effects may last days, weeks, or even months. Certain effects may even be permanent.
Bottom Line
The amount of time that cannabis remains in your system following a single use varies greatly depending on individual characteristics such as body fat, metabolism, frequency of use, and mode of intake. Frequent users may maintain traces of THC for weeks, whereas infrequent users may test positive for as little as a few days. Hair tests can disclose usage for up to 90 days, while blood and saliva tests identify more recent use. Urine tests are the most popular and have varying detection durations. The duration that THC and its metabolites are detectable will ultimately depend on a number of factors, including dose, strength, and individual body chemistry.
PEE IN A CUP COMING UP, READ ON..
Driving Under The Influence of THC In Vermont
Long shot adult-use legalization effort launches in anti-marijuana Idaho
Latest Trump Weed Rumor – Trump Will Federally Deschedule and Decriminalize Cannabis, but Not Legalize It
Webinar Replay: Post-Election Cannabis Wrap – Smoke ’em if You’ve Got ’em
I Had Just One Puff
Marijuana firms Eaze, Green Dragon find new life after $10 million capital infusion
Get some rest on Modified Grapes—November’s Leafly HighLight
Is Kratom Addictive? Understanding Dependence, Risks, and Safe Usage
New Rule, December 5: Oregon Cannabis Retailers, Processors and Labor Peace Agreements
The CBD Dog Treat Guide
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
Trending
-
Cannabis News2 years ago
Distressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years ago
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years ago
What you Need to Know
-
drug testing11 months ago
Drug Testing for Marijuana – The Joint Blog
-
Education2 years ago
NCIA Write About Their Equity Scholarship Program
-
Cannabis2 years ago
It has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years ago
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years ago
A new April 20 cannabis contest includes a $40,000 purse